European Regulatory Round-Up: Research Partners And Parallel Traders
Executive Summary
EU’s Innovative Medicines Initiative Builds On Closer U.S. Ties
You may also be interested in...
Drug Firms Join In Stem Cell R&D Under EU Innovative Medicines Initiative
The latest public-private partnerships to be announced under the EU’s Innovative Medicines Initiative includes the StemBANCC project involving 10 pharmaceutical companies and 23 academic institutions working together to develop patient-derived induced stem cell lines for drug development.
Servier Research Deals Suggest Business-As-Usual For Scandal-Ridden Firm
Still reeling from the Mediator scandal, Servier's two latest cancer research deals suggest the French company is trying to move forward.
Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders
Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.